Key result
This review summarizes the goals, pharmacokinetics, pharmacodynamics, and clinical data of available and developing anticoagulant therapies for percutaneous coronary intervention.
This review summarizes the goals, pharmacology, and clinical data of anticoagulant therapy during percutaneous coronary intervention.
Answers are grounded in this paper and cite their sources.
Provides clinicians a consolidated PCI anticoagulation reference; leaves open optimal use of developing agents.
P ercutaneous coronary intervention (PCI) is the most commonly performed invasive therapeutic cardiac procedure and plays an important role in the treatment of ischemic heart disease. Since the first description of coronary angioplasty in a human by Gruntzig, 1 the technique, equipment, and associated pharmacotherapy have undergone substantial evolution, leading to significant improvements in periprocedural complications. The purpose of this review is to summarize the goals of anticoagulant therapy during PCI, the pharmacokinetics and pharmacodynamics of available agents, and the clinical data surrounding each agent and to identify new agents in development.
No takes yet. Share an insight, caveat, or question.
Rao et al. (2010) conducted a review in Ischemic heart disease undergoing percutaneous coronary intervention. Anticoagulant therapy was evaluated. This review summarizes the goals, pharmacokinetics, pharmacodynamics, and clinical data of available and developing anticoagulant therapies for percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: